Cargando…

A Phase 3 Study of Enarodustat in Anemic Patients with CKD not Requiring Dialysis: The SYMPHONY ND Study

INTRODUCTION: Enarodustat (JTZ-951) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that might be a new therapeutic approach for managing anemia in patients with chronic kidney disease (CKD). We evaluated the efficacy (noninferiority to darbepoetin alfa [DA]) and safety of enarodust...

Descripción completa

Detalles Bibliográficos
Autores principales:	Akizawa, Tadao, Nangaku, Masaomi, Yamaguchi, Takuhiro, Koretomo, Ryosuke, Maeda, Kazuo, Miyazawa, Yuya, Hirakata, Hideki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258589/ https://www.ncbi.nlm.nih.gov/pubmed/34307978 http://dx.doi.org/10.1016/j.ekir.2021.04.037

Ejemplares similares

Two long‐term phase 3 studies of enarodustat (JTZ‐951) in Japanese anemic patients with chronic kidney disease not on dialysis or on maintenance hemodialysis: SYMPHONY ND‐Long and HD‐Long studies
por: Akizawa, Tadao, et al.
Publicado: (2021)

Treatment of anemia associated with chronic kidney disease with the HIF prolyl hydroxylase inhibitor enarodustat: A review of the evidence
por: Fujikawa, Ryo, et al.
Publicado: (2022)

Hyporesponsiveness to erythropoiesis-stimulating agent in non-dialysis-dependent CKD patients: The BRIGHTEN study
por: Narita, Ichiei, et al.
Publicado: (2022)

Phase 3 Study of Roxadustat to Treat Anemia in Non–Dialysis-Dependant CKD
por: Akizawa, Tadao, et al.
Publicado: (2021)

Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan
por: Tanaka, Tetsuhiro, et al.
Publicado: (2018)

Biopsy-proven CKD etiology and outcomes: the Chronic Kidney Disease Japan Cohort (CKD-JAC) study
por: Hamano, Takayuki, et al.
Publicado: (2022)

Renal Hypoxia in CKD; Pathophysiology and Detecting Methods
por: Hirakawa, Yosuke, et al.
Publicado: (2017)

Epigenetic memory contributing to the pathogenesis of AKI-to-CKD transition
por: Tanemoto, Fumiaki, et al.
Publicado: (2022)

Higher hemoglobin levels using darbepoetin alfa and kidney outcomes in advanced chronic kidney disease without diabetes: a prespecified secondary analysis of the PREDICT trial
por: Maruyama, Shoichi, et al.
Publicado: (2023)

Survival and predictive factors in dialysis patients with COVID-19 in Japan: a nationwide cohort study
por: Kikuchi, Kan, et al.
Publicado: (2021)

Randomized Clinical Trial on the Effect of Bardoxolone Methyl on GFR in Diabetic Kidney Disease Patients (TSUBAKI Study)
por: Nangaku, Masaomi, et al.
Publicado: (2020)

Treatment satisfaction with molidustat in CKD-related anemia in non-dialysis patients: a post-hoc analysis of two clinical trials
por: Yamamoto, Hiroyasu, et al.
Publicado: (2023)

Initial responsiveness to darbepoetin alfa and its contributing factors in non-dialysis chronic kidney disease patients in Japan
por: Hayashi, Terumasa, et al.
Publicado: (2020)

Clinical significance of parathyroid intervention on CKD-MBD management
por: Ogata, Hiroaki, et al.
Publicado: (2008)

Control of severe hyperparathyroidism in dialysis patients with nodular hyperplasia
por: Fukagawa, Masafumi, et al.
Publicado: (2008)

Safety of daprodustat in patients with anemia of chronic kidney disease: A pooled analysis of phase 3 studies in Japan
por: Nangaku, Masaomi, et al.
Publicado: (2022)

Editorial: Management of Patients With Non-dialysis Dependent Chronic Kidney Disease (ND-CKD)
por: Provenzano, Michele, et al.
Publicado: (2022)

Hyperbaric area index calculated from ABPM elucidates the condition of CKD patients: the CKD-JAC study
por: Iimuro, Satoshi, et al.
Publicado: (2014)

Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study
por: Nangaku, Masaomi, et al.
Publicado: (2021)

Extraperitoneal Placement of a Peritoneal Dialysis Catheter
por: Nakamura, Yasuna, et al.
Publicado: (2018)

NPT-IIb Inhibition Does Not Improve Hyperphosphatemia in CKD
por: Larsson, Tobias E., et al.
Publicado: (2017)

Clinical parameters among patients in Japan with anemia and non-dialysis-dependent chronic kidney disease with and without diabetes mellitus who received roxadustat
por: Akizawa, Tadao, et al.
Publicado: (2022)

Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients
por: Tsuruya, Kazuhiko, et al.
Publicado: (2019)

Risk factors for CKD progression in Japanese patients: findings from the Chronic Kidney Disease Japan Cohort (CKD-JAC) study
por: Inaguma, Daijo, et al.
Publicado: (2016)

The anemic cat
por: Lappin, Michael R.
Publicado: (2006)

Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors vs. erythropoiesis-stimulating agents on iron metabolism in non-dialysis-dependent anemic patients with CKD: A network meta-analysis
por: Yang, Junlan, et al.
Publicado: (2023)

A prospective observational study of early intervention with erythropoietin therapy and renal survival in non-dialysis chronic kidney disease patients with anemia: JET-STREAM Study
por: Akizawa, Tadao, et al.
Publicado: (2016)

Peritoneal Dialysis-Related Peritonitis Caused by Streptococcus oralis
por: Kotani, Akihiro, et al.
Publicado: (2021)

Association of adiposity with hemoglobin levels in patients with chronic kidney disease not on dialysis
por: Honda, Hirokazu, et al.
Publicado: (2017)

Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism
por: Akizawa, Tadao, et al.
Publicado: (2019)

Ketoanalogues supplementation decreases dialysis and mortality risk in patients with anemic advanced chronic kidney disease
por: Wu, Che-Hsiung, et al.
Publicado: (2017)

Correction to: Association of adiposity with hemoglobin levels in patients with chronic kidney disease not on dialysis
por: Honda, Hirokazu, et al.
Publicado: (2018)

Mechanism of Anemic Murmurs
por: Rochester, DeLancey
Publicado: (1890)

Determinants for Anemic Retinopathy
por: Venkatesh, Ramesh, et al.
Publicado: (2023)

Association between serum iron markers, iron supplementation and cardiovascular morbidity in pre-dialysis chronic kidney disease
por: Hasegawa, Takeshi, et al.
Publicado: (2023)

Dialysis‐related practice patterns among hemodialysis patients with cancer
por: Nishiwaki, Hiroki, et al.
Publicado: (2018)

Design and baseline characteristics of the LANDMARK study
por: Ogata, Hiroaki, et al.
Publicado: (2016)

Psychological Flexibility and Depression in Advanced CKD and Dialysis
por: Iida, Hidekazu, et al.
Publicado: (2020)

Nephrologists’ Perspectives on Gender Disparities in CKD and Dialysis
por: Tong, Allison, et al.
Publicado: (2021)

Molidustat for Japanese Patients With Renal Anemia Receiving Dialysis
por: Akizawa, Tadao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mbdb5t5t9kfcpei3bjm0o747eh